Tempus AI rises as it expands cancer research partnership with Gilead

ReutersApr 9, 2026 12:49 PM

Shares of healthcare AI firm Tempus AI TEM.O rise 1.5% to $47.99 premarket

Co says it has expanded its multi-year partnership with Gilead GILD.O to support cancer drug research

Collaboration gives Gilead wider access to Tempus’ real-world patient data and AI tools, which analyze medical records from cancer patients - TEM

Gilead will use the platform to design clinical trials, choose drug targets and study treatment outcomes, co says

Says partnership aims to speed up development of cancer medicines by combining Tempus’ data insights with Gilead’s drugmaking expertise

Gilead has previously utilized TEM's data for its oncology research, including trial design, health outcomes analysis and clinical evidence

As of last close, stock down ~20% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Nvidia Releases Open-Source Quantum AI Model Ising, Quantum Computing Sector Rises Collectively, IonQ Gains Over 20%

TradingKey - On April 14, 2026, local time, NVIDIA (NVDA) officially released NVIDIA Ising, an open-source quantum AI model licensed under Apache-2.0. The model focuses on two core engineering challenges: quantum processor calibration and quantum error correction.

Micron Surges 9% to Record High as Nasdaq Hits 10-Day Winning Streak: Will Memory Stocks Lead the Bull Market’s Return?

TradingKey - At the U.S. market close on April 14, the Nasdaq completed a 10-day winning streak, marking its longest since 2021; NVIDIA (NVDA) , AMD also recorded 10-day winning streaks. Micron (MU) surged 9% to a new closing high, leading the U.S. chip sector. The Philadelphia Semiconductor Index r

Anthropic IPO vs OpenAI IPO: Can an $800 Billion Valuation Help Anthropic Claim the First Large Model Stock?

TradingKey – An $800 billion valuation for Anthropic: this is the most staggering figure in the global AI investment circle as of April 2026. According to Business Insider, several venture capital firms have proactively extended investment offers to Claude developer Anthropic, with valuations reaching up to $800 billion—double the $380 billion valuation from its Series G round just two months prior. Notably, Anthropic has yet to accept any new funding, despite Silicon Valley capital vying for a stake. With the company set to launch its IPO as early as October 2026, the battle for the title of "the first public LLM stock" between the Anthropic IPO and the OpenAI IPO has officially begun.

Software Stocks Are Continuing to Rebound, Should Investors Buy Oracle or Microsoft Now?

TradingKey - Following a 12.7% single-day surge in Oracle's (ORCL.US) share price on April 13, which added $50.4 billion to its market capitalization, the stock extended its rally on April 14, rising another 4.74% to $163, as trading volume expanded to $9.783 billion.

ASML 2026 Q1 Earnings Preview: Valuations Are Already at Highs, Can AI Orders Support Growth Expectations?

TradingKey - Global lithography leader ASML is set to disclose its first-quarter 2026 financial results on April 15. Market focus on the company's short-term performance volatility and long-term growth potential continues to intensify.

Featured Tools